Business Context and Reporting Period
This Form 8-K Current Report was filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on December 28, 2006, covering events occurring on December 21, 2006. The company is incorporated in Florida and maintains its principal executive offices in New York, New York.
Key Financial Metrics and Capital Structure
The filing details a private placement transaction rather than standard operating financial results.
- Capital Raised: Aggregate gross proceeds of $1,000,000.
- Securities Issued: 1,000,000 shares of common stock and 500,000 warrants.
- Warrant Terms: Immediately exercisable at $1.25 per share; exercisable within six months of issuance.
- Transaction Costs: $80,000 paid to a selling agent.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net profit, operating cash flow, or margins.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or current liquidity ratios, though the capital raise addresses funding needs.
Material Changes and Corporate Events
Two significant material events were reported:
- Unregistered Sales of Equity: The company closed a private placement with an overseas institutional investor under Section 4(2) of the Securities Act and Regulation D. The agreement includes registration rights requiring the company to file a registration statement for resale of securities by May 14, 2007, or within 15 days of raising an additional $5,000,000.
- Change in Certifying Accountant: On December 22, 2006, Lazar Levine & Felix LLP resigned as the company's principal accountants. The audit report for the fiscal year ended January 31, 2006, contained an explanatory paragraph regarding the company's ability to continue as a going concern. No disagreements on accounting principles or practices were reported during the most recent fiscal year.
Outlook, Risks, and Contingencies
The filing highlights a specific contingency regarding the company's financial stability: the previous auditor's report included a "going concern" explanatory paragraph. Additionally, the company faces a contractual obligation to file a registration statement for the newly issued securities by May 14, 2007, or sooner if a $5,000,000 financing threshold is met. The filing does not provide specific management commentary on future product development or market outlook.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Cardiff Oncology, Inc.) and the actual registrant (Xenomics, Inc.).
- Confirm the status of the "going concern" warning noted in the prior fiscal year's audit report.
- Monitor the company's progress toward the $5,000,000 financing threshold to determine the deadline for the required registration statement.
- Review the identity and background of the overseas institutional investor.
- Check for the appointment of a new principal accountant following the resignation of Lazar Levine & Felix LLP.